Published in Clin Dev Immunol on December 06, 2011
Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity (2014) 2.06
NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 1.14
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Transm (Vienna) (2013) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One (2014) 0.88
Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 0.87
Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci (2015) 0.82
The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81
A discrete population of IFN λ-expressing BDCA3hi dendritic cells is present in human thymus. Immunol Cell Biol (2015) 0.80
Osteosarcoma Overview. Rheumatol Ther (2016) 0.79
Interferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulation. Int J Mol Sci (2014) 0.78
Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. J Hepatol (2013) 0.78
Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chin J Cancer (2015) 0.77
Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response. Immunology (2014) 0.76
IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy (2016) 0.76
Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol (2014) 0.76
Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured. BMC Cancer (2014) 0.76
Adenovirus expressing IFN-λ (Ad/hIFN-λ) produced anti-tumor effects through inducing apoptosis in human tongue squamous cell carcinoma cell. Int J Clin Exp Med (2015) 0.75
IFN-λ: A New Inducer of Local Immunity against Cancer and Infections. Front Immunol (2016) 0.75
IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol (2017) 0.75
IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. J Invest Dermatol (2015) 0.75
Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells. Cell J (2015) 0.75
Interferon-lambda3 (IFN-λ3) and its cognate receptor subunits in tree shrews (Tupaia belangeri): genomic sequence retrieval, molecular identification and expression analysis. PLoS One (2013) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75
IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4.70
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21
Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91
Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol (2002) 3.83
An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 3.75
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 3.46
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25
Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis (2005) 2.98
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int (2008) 2.65
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A (2011) 2.47
Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2008) 2.40
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 2.39
Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 2.38
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res (2006) 2.34
Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 2.28
Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 2.18
Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 2.15
IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res (2008) 2.03
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol (2009) 1.88
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
IL-28 and IL-29: newcomers to the interferon family. Biochimie (2007) 1.81
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 1.76
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol (2010) 1.66
Antitumor activity of IFN-lambda in murine tumor models. J Immunol (2006) 1.63
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 1.60
Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy (2008) 1.56
Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol (2008) 1.50
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther (2006) 1.48
IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther (2008) 1.45
IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med (2011) 1.44
IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol (2007) 1.35
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol (2009) 1.27
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
Interferon lambdas: the next cytokine storm. Gut (2011) 1.25
Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun (2006) 1.24
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24
Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol (2009) 1.22
Regulation of apoptosis by type III interferons. Cell Prolif (2008) 1.19
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol (2010) 1.18
Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun (2006) 1.17
Hepatocellular carcinoma. Hepatology (1998) 1.16
IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood (2009) 1.15
Interferons and apoptosis. J Interferon Cytokine Res (2003) 1.15
Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol (2005) 1.12
Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res (2007) 1.11
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology (2000) 1.10
Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology (2008) 1.10
Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J (2008) 1.06
IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J Immunol (1999) 1.05
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04
Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia (2010) 1.02
The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev (2004) 1.01
Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg (2003) 1.00
Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis (2010) 0.97
Innate immunity in the pathogenesis of virus-induced asthma exacerbations. Proc Am Thorac Soc (2007) 0.96
Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov (2008) 0.91
Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology (2008) 0.88
A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia (2008) 0.86
Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res (1995) 0.84
Antitumour effects of interferons: past, present and future. Br J Haematol (1991) 0.84
[IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci (Paris) (2010) 0.81
Interaction of IFN alpha/beta with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice. Int J Cancer (1994) 0.81
Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta. Int J Cancer (1994) 0.81
Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg (2008) 0.80
Interferons in the treatment of solid tumors. Cancer Treat Res (2005) 0.80
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res (2006) 2.34
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A (2007) 1.08
The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol (2010) 1.07
Brain injury expands the numbers of neural stem cells and progenitors in the SVZ by enhancing their responsiveness to EGF. ASN Neuro (2009) 1.01
Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis (2010) 0.97
Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol (2007) 0.92
Egr-1 is a critical regulator of EGF-receptor-mediated expansion of subventricular zone neural stem cells and progenitors during recovery from hypoxia-hypoglycemia. ASN Neuro (2013) 0.79
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. PLoS One (2012) 0.77
Correction: Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections. PLoS Pathog (2016) 0.75